Akèy › Kansè Glann Salivè › Tennessee
Etid klinik pou Kansè Glann Salivè nan Tennessee
5 etid pou Kansè Glann Salivè ap chèche patisipan nan sit nan Tennessee.
Vil nan Tennessee
Tèks ofisyèl etid la (Anglè)
DESTINY-PANTUMOUR04
- Research Site, Nashville
Ap rekriteEtid obsèvasyon
Laj 18 a 130 · Tout sèks · Mizajou Sep 25, 2026 · NCT07124000Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
- Vanderbilt University/Ingram Cancer Center, Nashville
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT05408845A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
- SCRI Oncology Partners, Nashville
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 10, 2026 · NCT06695845Tissue Sample Collection From Patients With Head and Neck Cancer and From Healthy Participants
- Vanderbilt-Ingram Cancer Center - Cool Springs, Nashville
- Vanderbilt-Ingram Cancer Center at Franklin, Nashville
- Veterans Affairs Medical Center - Nashville, Nashville
- ak 1 plis
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Oct 28, 2025 · NCT00898638A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
- Tennessee Oncology, Nashville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2025 · NCT05941507Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.